Contact PI/Project LeaderPARENT, CAROLE ANNE Other PIs
Awardee OrganizationUNIVERSITY OF MICHIGAN AT ANN ARBOR
Description
Abstract Text
ABSTRACT
The property of sensing and propagating external cues that drive directional migration is a fundamental property
of biological systems, and is essential to physiological and pathological processes including embryogenesis,
adult tissue homeostasis, inflammation and immune responses, and metastatic invasion. This proposal aims at
understanding how chemotactic signals are packaged and propagated between neighboring cells during
chemotaxis. To do so, we study human neutrophils, the most abundant leukocytes in normal human blood. When
exposed to primary chemoattractants like N-formyl-Met-Leu-Phe (fMLF), which is secreted by pathogens
invading the body and by necrotic cells at sites of injury, neutrophils rapidly undergo polarization that allows them
to efficiently migrate up the fMLF gradient. As they react to fMLF, neutrophils secrete secondary
chemoattractants that serve to maintain the robustness and sensitivity to the primary chemoattractant signals.
We established that the secondary chemoattractant leukotriene B4 (LTB4) is required for the massive recruitment
of neutrophils to sites of injury in vitro and in vivo. In order for LTB4 to act as a bona fide signal relay molecule,
it must be released in a form that enables the generation of a stable gradient during chemotaxis. In this context,
we established that LTB4 is packaged in vesicles in chemotaxing neutrophils as a way to effectively disseminate
gradients between neighboring cells. We found that LTB4 and its synthesizing enzymes – 5-lipoxigenase (5-LO)
and 5-LO activating protein (FLAP) - localize to intracellular multivesicular bodies (MBVs) which, upon
chemoattractant stimulation, release their content as exosomes, thereby acting as a packaging mechanism to
relay chemotactic signals. Further, we found that MVB biogenesis appears to be initiated at the nuclear envelope
(NE) in activated neutrophils. We hypothesize that the NE is a novel site of MVB formation that enables
packaging of the LTB4 synthetic machineryinto secretory MVBs that release exosomes to relay of signals during
neutrophil chemotaxis. To test this hypothesis, in Aim 1 we will directly visualize 5-LO and FLAP dynamics in
live cells using mCherry/GFP fusions and photoactivatable reporters under normal conditions and when
endocytosis is blocked. We will also assess the role of FLAP clustering as a driving force for MVB biogenesis at
the NE, by generating FLAP mutants with distinct affinities for the 5-LO substrate arachidonic acid. Since integral
membrane proteins clustering is considered a hallmark of ordered membrane microdomains, in Aim 2 we will
define the role of nuclear lipid micro-domains in MVB biogenesis. Finally, in Aim 3 we will establish the role of
membrane remodeling complexes in the formation of the nuclear MVBs by assessing the role of ESCRTs in this
process and identify accessory proteins involved in NE remodeling. This project is poised to provide much
needed insight into the mechanisms regulating the genesis of chemotactic signals during neutrophil chemotaxis
and will bring unprecedented knowledge into the role of the NE in the biogenesis of MVBs and in the interplay
between lipid- and ESCRT-dependent pathways in their biogenesis.
Public Health Relevance Statement
NARRATIVE
The rapid recruitment of white blood cells to sites of tissue injury or infection is a vital determinant
of health and its deregulation can lead to chronic disease. This proposal aims at understanding
how chemotactic signals are packaged and propagated between neighboring neutrophils, a type
of white blood cell critical to innate immunity responses, as they are being recruited to sites of
injury or infection. We propose to identify the mechanisms by which exosomes, which are small
membrane-bound elements with a key role in signal propagation, are being generated
intracellularly from multivesicular bodies using cell biological, biochemical and genetic
approaches.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
073133571
UEI
GNJ7BBP73WE9
Project Start Date
10-July-2020
Project End Date
30-June-2025
Budget Start Date
10-July-2020
Budget End Date
30-June-2021
Project Funding Information for 2020
Total Funding
$530,993
Direct Costs
$344,867
Indirect Costs
$186,126
Year
Funding IC
FY Total Cost by IC
2020
National Institute of Allergy and Infectious Diseases
$530,993
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01AI152517-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01AI152517-01
Patents
No Patents information available for 1R01AI152517-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01AI152517-01
Clinical Studies
No Clinical Studies information available for 1R01AI152517-01
News and More
Related News Releases
No news release information available for 1R01AI152517-01
History
No Historical information available for 1R01AI152517-01
Similar Projects
No Similar Projects information available for 1R01AI152517-01